Preclinical trials of a cancer vaccine have been completed in Russia, and the first phase of clinical trials will begin after the Ministry of Health gives permission, reports Andrey Kaprin, the chief oncologist of the Ministry of Health, general director of the Ministry's National Medical Research Center of Radiology, and academician of the Russian Academy of Sciences.
"We have completed the preclinical phase. Now a letter has been sent to the Ministry of Health so that they will allow us to begin the first phase of trials," TASS reports him as saying.
As soon as the department issues permission, an announcement will be published on the website about recruiting volunteers with medical indications, Kaprin noted.
The academician also added that the vaccine will be contraindicated for patients who have not completed chemotherapy, as a result of which patients may be denied the vaccine until the end of the course of treatment.
In early June, Health Minister Mikhail Murashko said that they expect to receive the results of preclinical trials of a cancer vaccine only by the end of 2024, after which they will begin clinical trials.
According to one of the developers, the drug will be administered to those already sick so that their immune system learns to distinguish malignant cells.
"We have completed the preclinical phase. Now a letter has been sent to the Ministry of Health so that they will allow us to begin the first phase of trials," TASS reports him as saying.
As soon as the department issues permission, an announcement will be published on the website about recruiting volunteers with medical indications, Kaprin noted.
The academician also added that the vaccine will be contraindicated for patients who have not completed chemotherapy, as a result of which patients may be denied the vaccine until the end of the course of treatment.
In early June, Health Minister Mikhail Murashko said that they expect to receive the results of preclinical trials of a cancer vaccine only by the end of 2024, after which they will begin clinical trials.
According to one of the developers, the drug will be administered to those already sick so that their immune system learns to distinguish malignant cells.